Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prelude Therapeutics (PRLD) Non Operating Income (2024 - 2025)

Prelude Therapeutics (PRLD) has disclosed Non Operating Income for 2 consecutive years, with $891000.0 as the latest value for Q4 2025.

  • Quarterly Non Operating Income fell 82.53% to $891000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.1 million through Dec 2025, down 59.59% year-over-year, with the annual reading at $5.1 million for FY2025, 59.59% down from the prior year.
  • Non Operating Income hit $891000.0 in Q4 2025 for Prelude Therapeutics, up from $693000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $5.1 million in Q4 2024 to a low of $693000.0 in Q3 2025.